Occidental Announces Dividend HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) announced today that its Board of Directors declared a regular quarterly dividend of $0.24 per share on common stock, payable on October 15, 2025, to stockholders of record as of the close of business on September 10, 2025. About Occidental is an international energy company with assets primarily in the United States, the Middle East and North Africa. We are one of the largest in the U.S., including a leading producer in the Permian and DJ basins, and offshore Gulf of America. Our provides flow assu...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Occidental to Announce Second Quarter Results Wednesday, August 6, 2025; Hold Conference Call Thursday, August 7, 2025 HOUSTON, July 01, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) will announce its second quarter 2025 financial results after close of market on Wednesday, August 6, 2025, and will hold a conference call to discuss the results on Thursday, August 7, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international callers dial 1-412-317-5417) or via webcast at Participants may pre-register for the conference call at . Sec...
IGM Biosciences Enters into Agreement to Be Acquired by Concentra Biosciences for $1.247 in Cash per Share Plus a Contingent Value Right MOUNTAIN VIEW, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company that has focused on developing engineered IgM-based therapeutic antibodies, today announced that it has entered into a definitive merger agreement (the “Merger Agreement”) with Concentra Biosciences, LLC (“Concentra”), whereby Concentra will acquire IGM Biosciences for $1.247 in cash per share of IGM Biosciences common stock (“Common Sto...
Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) ("Titan" or the "Company") announced today that, pursuant to a securities purchase agreement (the “Purchase Agreement”) with Blue Harbour Asset Management L.L.C-FZ (“Blue Harbour”), it has completed a private placement of the Company’s newly designated Series C Convertible Preferred Stock (the “Preferred Stock”). Pursuant to the Purchase Agreement, Blue Harbour purchased 60,000 shares of Preferred Stock for an aggr...
n this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd. NEW YORK, June 03, 2025 (GLOBE NEWSWIRE) -- Titan Pharmaceuticals, Inc. (NASDAQ: TTNP) (“Titan” or the “Company”) announced today the filing by Black Titan Corporation with the U.S. Securities and Exchange Commission (“SEC”) of a registration statement on Form F-4 in connection with the proposed combination of Titan and TalenTec Sdn. Bhd. (f/k/a KE Sdn. Bhd.) (“TalenTec”), which includes Titan’s preliminary proxy statement (the “Form F-4”) As previously announced on ...
Kalaris to Present at Noble Capital Markets 2025 Emerging Growth Equity Conference PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will present at the upcoming Noble Capital Markets 2025 Emerging Growth Virtual Equity Conference. The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience. Details: ...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Occidental Petroleum Corporation (OXY) and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 21 May 2025 in which we reassessed the appropriateness of the rating...
Kalaris to Participate at Stifel Ophthalmology Forum PALO ALTO, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced that management will participate at an upcoming Fireside Chat at the Stifel 2025 Virtual Ophthalmology Forum. Details: Type: Fireside ChatSpeakers: Andrew Oxtoby, Chief Executive Officer & Matthew Feinsod, Chief Medical OfficerDate: Tuesday, May 27th, 2025Time: 08:00 am ETLoca...
Occidental and ADNOC’s XRG Agree to Evaluate Joint Venture to Develop South Texas Direct Air Capture Hub XRG to consider investing up to $500 million for the development of 1PointFive’s 500,000 tonne-capacity DAC facility HOUSTON, May 16, 2025 (GLOBE NEWSWIRE) -- Occidental (NYSE: OXY) and its subsidiary 1PointFive today announced an agreement with XRG, ADNOC’s investment company, to evaluate a potential joint venture to develop a Direct Air Capture (DAC) facility in South Texas. As part of the joint venture, XRG will consider investing up to $500 million for the development of a DAC fa...
Kalaris Reports First Quarter 2025 Financial Results and Provides Business Highlights Actively enrolling nAMD patients in a Phase 1 trial of TH103, a novel, differentiated anti-VEGF agent engineered to potentially provide longer-lasting and increased anti-VEGF activity to treat neovascular and exudative diseases of the retina; initial clinical data is expected in Q4 2025 Cash and cash equivalents of $101M as of March 31, 2025, expected to fund operations into Q4 2026 PALO ALTO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinica...
Occidental Announces First Quarter 2025 Results HOUSTON, May 07, 2025 (GLOBE NEWSWIRE) -- (NYSE: OXY) today announced its first quarter 2025 financial results. The earnings release and accompanying financial schedules can be accessed via the section of the company’s website, . The earnings release is also available on the U.S. Securities and Exchange Commission’s website at sec.gov. The company will hold a conference call to discuss the results on Thursday, May 8, 2025, at 1 p.m. Eastern/12 p.m. Central. The conference call may be accessed by calling 1-866-871-6512 (international calle...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.